EMD-27909

Single-particle
3.3 Å
EMD-27909 Deposition: 20/08/2022
Map released: 07/12/2022
Last modified: 30/10/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-27909

calcium channel

EMD-27909

Single-particle
3.3 Å
EMD-27909 Deposition: 20/08/2022
Map released: 07/12/2022
Last modified: 30/10/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Homo sapiens
Sample: Cav1.3
Fitted models: 8e5b (Avg. Q-score: 0.467)

Deposition Authors: Gao S, Yao X, Yan N
Structural basis for the severe adverse interaction of sofosbuvir and amiodarone on L-type Ca v channels.
Yao X, Gao S, Wang J, Li Z, Huang J , Wang Y, Wang Z, Chen J, Fan X , Wang W, Jin X, Pan X, Yu Y, Lagrutta A, Yan N
(2022) Cell , 185 , 4801 - 4810.e13
PUBMED: 36417914
DOI: doi:10.1016/j.cell.2022.10.024
ISSN: 1097-4172
Abstract:
Drug-drug interaction of the antiviral sofosbuvir and the antiarrhythmics amiodarone has been reported to cause fatal heartbeat slowing. Sofosbuvir and its analog, MNI-1, were reported to potentiate the inhibition of cardiomyocyte calcium handling by amiodarone, which functions as a multi-channel antagonist, and implicate its inhibitory effect on L-type Cav channels, but the molecular mechanism has remained unclear. Here we present systematic cryo-EM structural analysis of Cav1.1 and Cav1.3 treated with amiodarone or sofosbuvir alone, or sofosbuvir/MNI-1 combined with amiodarone. Whereas amiodarone alone occupies the dihydropyridine binding site, sofosbuvir is not found in the channel when applied on its own. In the presence of amiodarone, sofosbuvir/MNI-1 is anchored in the central cavity of the pore domain through specific interaction with amiodarone and directly obstructs the ion permeation path. Our study reveals the molecular basis for the physical, pharmacodynamic interaction of two drugs on the scaffold of Cav channels.